Disc Medicine, Inc. - Common Stock, $0.0001 par value per share (IRON)
CUSIP: 254604101
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Shares outstanding
- 37,778,373
- Total 13F shares
- 27,576,793
- Share change
- +5,317,837
- Total reported value
- $1,242,993,864
- Put/Call ratio
- 34%
- Price per share
- $45.07
- Number of holders
- 119
- Value change
- +$212,594,407
- Number of buys
- 81
- Number of sells
- 64
Quarterly Holders Quick Answers
What is CUSIP 254604101?
CUSIP 254604101 identifies IRON - Disc Medicine, Inc. - Common Stock, $0.0001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 254604101:
Top shareholders of IRON - Disc Medicine, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Braden M. Leonard |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
5,247,500
|
$354,993,375 | — | 26 Oct 2022 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
6.3%
|
2,389,902
|
$148,795,299 | — | 31 Mar 2024 | |
| Atlas Venture Life Science Advisors, LLC |
13F
|
Company |
6.1%
|
2,287,233
|
$142,403,127 | — | 31 Mar 2024 | |
| Atlas Venture Fund X, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,600,512
|
$108,274,637 | — | 23 Jan 2024 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
4.5%
|
1,702,237
|
$105,981,276 | — | 31 Mar 2024 | |
| Bain Capital Life Sciences Investors, LLC |
13F
|
Company |
3.5%
|
1,317,213
|
$82,009,681 | — | 31 Mar 2024 | |
| Novo Holdings A/S |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,090,772
|
$73,790,726 | — | 28 Jun 2023 | |
| STATE STREET CORP |
13F
|
Company |
2.9%
|
1,091,211
|
$67,938,797 | — | 31 Mar 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
2.5%
|
944,213
|
$58,788,000 | — | 31 Mar 2024 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
2.5%
|
939,866
|
$58,516,057 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
2.4%
|
901,595
|
$56,133,306 | — | 31 Mar 2024 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
2.1%
|
785,000
|
$48,874,100 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.1%
|
782,751
|
$48,734,077 | — | 31 Mar 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
1.8%
|
670,482
|
$41,744,210 | — | 31 Mar 2024 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
1.8%
|
665,535
|
$41,436,209 | — | 31 Mar 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.5%
|
574,464
|
$35,766,129 | — | 31 Mar 2024 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
1.4%
|
521,773
|
$32,464,972 | — | 31 Mar 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
1.3%
|
496,881
|
$30,935,811 | — | 31 Mar 2024 | |
| James B. Tananbaum |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
428,745
mixed-class rows
|
$27,837,975 | — | 04 Oct 2021 | |
| FMR LLC |
13F
|
Company |
1.1%
|
403,532
|
$25,123,890 | — | 31 Mar 2024 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.96%
|
363,468
|
$22,629,518 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.86%
|
325,724
|
$20,279,576 | — | 31 Mar 2024 | |
| Saturn V Capital Management LP |
13F
|
Company |
0.67%
|
254,803
|
$15,864,035 | — | 31 Mar 2024 | |
| First Turn Management, LLC |
13F
|
Company |
0.67%
|
252,673
|
$15,731,421 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.65%
|
245,774
|
$15,304,229 | — | 31 Mar 2024 | |
| Polar Capital Holdings Plc |
13F
|
Company |
0.65%
|
244,928
|
$15,249,217 | — | 31 Mar 2024 | |
| Foresite Capital Management V, LLC |
13F
|
Company |
0.64%
|
243,513
|
$15,161,119 | — | 31 Mar 2024 | |
| Atlas Venture Opportunity Fund II, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
218,326
|
$14,769,754 | — | 29 Dec 2022 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.61%
|
231,797
|
$14,431,681 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.57%
|
213,691
|
$13,304,401 | — | 31 Mar 2024 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.56%
|
213,061
|
$13,265,177 | — | 31 Mar 2024 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
0.51%
|
193,240
|
$12,031,122 | — | 31 Mar 2024 | |
| Blue Owl Capital Holdings LP |
13F
|
Company |
0.41%
|
155,260
|
$9,666,488 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.36%
|
136,634
|
$8,506,832 | — | 31 Mar 2024 | |
| Cormorant Asset Management, LP |
13F
|
Company |
0.33%
|
125,000
|
$7,782,500 | — | 31 Mar 2024 | |
| LORD, ABBETT & CO. LLC |
13F
|
Company |
0.32%
|
119,312
|
$7,429,000 | — | 31 Mar 2024 | |
| MPM BioImpact LLC |
13F
|
Company |
0.29%
|
110,779
|
$6,897,101 | — | 31 Mar 2024 | |
| Artisan Partners Limited Partnership |
13F
|
Company |
0.29%
|
109,319
|
$6,806,201 | — | 31 Mar 2024 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.28%
|
107,593
|
$6,698,740 | — | 31 Mar 2024 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
0.27%
|
102,865
|
$6,404,375 | — | 31 Mar 2024 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.27%
|
102,016
|
$6,351,516 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.26%
|
97,388
|
$6,063,376 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.24%
|
92,093
|
$5,733,710 | — | 31 Mar 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.24%
|
89,253
|
$5,556,891 | — | 31 Mar 2024 | |
| Artia Global Partners LP |
13F
|
Company |
0.23%
|
87,040
|
$5,419,110 | — | 31 Mar 2024 | |
| S.c.a. Candriam |
13F
|
Individual |
0.21%
|
80,000
|
$4,980,800 | — | 31 Mar 2024 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.2%
|
76,800
|
$4,781,568 | — | 31 Mar 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.2%
|
74,777
|
$4,655,616 | — | 31 Mar 2024 | |
| Invesco Ltd. |
13F
|
Company |
0.19%
|
71,435
|
$4,447,543 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.18%
|
68,403
|
$4,258,770 | — | 31 Mar 2024 |
Institutional Holders of Disc Medicine, Inc. - Common Stock, $0.0001 par value per share (IRON) as of Q2 2024
As of 30 Jun 2024,
Disc Medicine, Inc. - Common Stock, $0.0001 par value per share (IRON) was held by
119 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
27,576,793 shares.
The largest 10 holders included
Paradigm Biocapital Advisors LP, Atlas Venture Life Science Advisors, LLC, Bain Capital Life Sciences Investors, LLC, ORBIMED ADVISORS LLC, WELLINGTON MANAGEMENT GROUP LLP, Frazier Life Sciences Management, L.P., BlackRock Inc., PRICE T ROWE ASSOCIATES INC /MD/, VANGUARD GROUP INC, and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C).
This page lists
119
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
125
Q2 2024 holders
119
Holder diff
-6
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.